Pityrosporoses encompass various Malassezia-driven conditions. Dandruff and seborrheic dermatitis are members of this family of disorders. Their precise pathomechanisms have not been completely elucidated so far. This review focuses on the role of corneocytes in these disorders. Malassezia yeasts are not evenly distributed at the surface of the stratum corneum. Rather, they are clumped on some corneocytes while other corneocytes in their vicinity are almost free of these microorganisms. The corneocytes heavily coated by yeasts suggest a cell-related defect in the mechanisms controlling the skin biocene including the natural antimicrobial peptides and nitric oxide. Most environmental factors influencing pityrosporoses indeed affect the natural human defenses against certain microorganisms. We frame as a hypothesis that the primary defect in some Malassezia-driven disorders resides in the corneocytes and their precursor keratinocytes.

1.
Hay RJ, Graham-Brown RA: Dandruff and seborrhoeic dermatitis: causes and management. Clin Exp Dermatol 1997;22:3–6.
2.
Piérard GE, Arrese JE, Piérard-Franchimont C, De Doncker P: Prolonged effect of antidandruff shampoos: time to recurrence of Malassezia ovalis colonization of skin. Int J Cosmet Sci 1997;19:111–117.
3.
Piérard-Franchimont C, Arrese JE, Durupt G, Ries G, Cauwenbergh G, Piérard GE: Correlation between Malassezia spp. load and dandruff severity. J Mycol Med 1998;8:83–86.
4.
Piérard-Franchimont C, Hermanns JF, Degreef H, Arrese JE, Piérard GE: From axioms to new insights into dandruff. Dermatology 2000;200:93–98.
5.
Gemmer CM, DeAngelis YM, Theelen B, Boekhout T, Dawson JT Jr: Fast and noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002;40:3350–3357.
6.
Gupta AK, Madzia SE, Batra R: Etiology and management of seborrheic dermatitis. Dermatology 2004;208:89–93.
7.
Baroni A, De Rosa R, De Rosa A, Donnarumma G, Catalanotti P: New strategies in dandruff treatment: growth control of Malassezia ovalis. Dermatology 2000;201:146–147.
8.
Faergemann J: Management of seborrhoeic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1:75–80.
9.
Piérard-Franchimont C, Piérard GE, Arrese JE, De Doncker P: Effect of ketoconazole 1% and 2% shampoos on severe dandruff and seborrhoeic dermatitis: clinical, squamometric and mycological assessments. Dermatology 2001;202:171–176.
10.
Piérard GE: Seborrheic dermatitis today, gone tomorrow? The link between the biocene and treatment. Dermatology 2003;206:187–188.
11.
Piérard-Franchimont C, Arrese JE, Piérard GE: Immunohistochemical aspects of the link between Malassezia ovalis and seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1995;4:14–19.
12.
Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G: Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001;144:549–556.
13.
Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A: The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol 2001;116:769–773.
14.
Gupta AK, Kohli Y, Summerbell RC, Faergemann J: Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001;39:243–251.
15.
Bergbrant IM, Faergemann J: Adherence of Malassezia furfur to human stratum corneum cells in vitro: a study of healthy individuals and patients with seborrhoeic dermatitis. Mycoses 1994;37:217–219.
16.
Boman HG: Innate immunity and the normal microflora. Immunol Rev 2000;173:5–16.
17.
Izadpanah A, Gallo RL: Antimicrobial peptides. J Am Acad Dermatol 2005;52:381–390.
18.
Donnarumma G, Paoletti I, Buommino E, Orlando M, Tufano MA, Baroni A: Malassezia furfur induces the expression of β-defensin-2 in human keratinocytes in a protein kinase C-dependent manner. Arch Dermatol Res 2004;295:474–481.
19.
Pirkhammer D, Seeber A, Honigsmann H, Tanew A: Narrow-band ultraviolet B (TL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000;143:964–968.
20.
Moehrle M, Dennenmoser B, Schlagenhauff B, Thomma S, Garbe C: High prevalence of seborrhoeic dermatitis on the face and scalp in mountain guides. Dermatology 2000;201:146–147.
21.
Fang FC: Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 1997;99:2818–2825.
22.
Bogdan C, Rollinghoff M, Diefenbach A: Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000;12:64–76.
23.
Tsatmali M, Graham A, Szatkowski D, Ancans J, Manning P, McNeil CJ, Graham AM, Thody AJ: Alpha-melanocyte-stimulating hormone modulates nitric oxide production in melanocytes. J Invest Dermatol 2000;114:520–526.
24.
Shimizu Y, Sakai M, Umemura Y, Ueda H: Immunohistochemical localization of nitric oxide synthase in normal human skin: expression of endothelial-type and inducible type nitric oxide synthase in keratinocytes. J Dermatol 1997;24:80–87.
25.
Romero-Graillet C, Aberdam E, Clement M, Ortonne JP, Ballotti R: Nitric oxide produced by ultraviolet-radiated keratinocytes stimulates melanogenesis. J Clin Invest 1997;99:635–642.
26.
Hermanns JF, Petit L, Martalo O, Piérard-Franchimont C, Cauwenbergh G, Piérard GE: Unraveling the patterns of subclinical phaeomelanin-enriched facial hyperpigmentation. Effect of depigmenting agents. Dermatology 2000;201:118–122.
27.
Petit L, Piérard-Franchimont C, Saint Léger D, Loussouarn G, Piérard GE: Subclinical speckled perifollicular melanosis of the scalp. Eur J Dermatol 2002;12:565–568.
28.
Petit L, Fogouang L, Uhoda I, Smitz S, Piérard-Franchimont C, Piérard GE: Regional variability in mottled subclinical melanoderma in the elderly. Exp Gerontol 2003;38:327–331.
29.
Uhoda E, Piérard-Franchimont C, Petit L, Piérard GE: The conundrum of skin pores in dermocosmetology. Dermatology 2005;210:3–7.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.